CAS: 145106-43-0; Tert-Butyl ((1S,2S)-2-Hydroxycyclopentyl)Carbamate

相似化合物

155837-16-4 945652-35-7 454170-16-2

上下游产品

CAS号24424-99-5 二碳酸二叔丁酯 | CAS号930-45-0 (1S,2S)-2-AMINO...

📜(1S,2S)-Trans-2-Azidocyclopentanol置于platinum(Iv) Oxide 氢气体系中,化学反应生成(1S,2S)-反式-N-Boc-2-氨基环戊醇
参考文献:Cis-Cyclopentyl Pna (Cppna) As Constrained Chiral Pna Analogues: Stereochemical Dependence Of Dna/rna Hybridizationelectronic Supplementary Information (Esi) Available: Experimental Procedures For The Synthesis Of Compounds,1H,13C NMR,Mass Spectral Data,Crystal Structural Data And Melting Curves For Triplexes. See Http://www.Rsc.Orgpdata/cc/b3/b317000D/
标题:Cis-Cyclopentyl Pna (Cppna) As Constrained Chiral Pna Analogues: Stereochemical Dependence Of Dna/rna Hybridizationelectronic Supplementary Information (Esi) Available: Experimental Procedures For The Synthesis Of Compounds,1H,13C NMR,Mass Spectral Data,Crystal Structural Data And Melting Curves For Triplexes. See Http://www.Rsc.Orgpdata/cc/b3/b317000D/
摘要:对具有cis-(1S,2R/1R,2S)-环戊基单元的pna-T寡聚物进行的dna/rna杂交研究表明,结合具有立体化学依赖性,并且能够区分rna和dna.
Doi:10.1039/b317000D

专利信息

专利号:US-8129411-B2
优先权日:2005-12-30
标题:Organic compounds
发明人：EHARA TAKERU; GROSCHE PHILIPP; IRIE OSAMU; IWAKI YUKI; KANAZAWA TAKANORI; KAWAKAMI SHIMPEI; KONISHI KAZUHIDE; MOGI MUNETO; SUZUKI MASAKI; YOKOKAWA FUMIAKI
权利人:EHARA TAKERU; GROSCHE PHILIPP; IRIE OSAMU; IWAKI YUKI; KANAZAWA TAKANORI; KAWAKAMI SHIMPEI; KONISHI KAZUHIDE; MOGI MUNETO; SUZUKI MASAKI; YOKOKAWA FUMIAKI; NOVARTIS AG
摘要:The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. n The compounds have the formula I′ n nwherein R1, R2, T, R3 and R4 are as defined in the specification.